Nuplazid 34 MG capsule 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FDJL8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,771
Award facts
- Contract value 100% obligated
- $11,771.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,771.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUPLAZID 34 mg capsules in quantities of 30 units. This firm fixed-price delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, carries no set-aside designation, indicating the award was made through open competition. The delivery order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply Department of Defense healthcare facilities worldwide with comprehensive pharmaceutical products and medical consumables.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status to compete effectively across the Defense Logistics Agency's medical supply operations. The company's primary indefinite delivery contract under PPV-G GEN V, valued at $499,999,999 with a completion date of December 31, 2036, positions it as a regional prime vendor contractor authorized to fulfill diverse and specialized pharmaceutical requirements for military healthcare operations globally. The company maintains no identified subcontractor relationships and has demonstrated substantial performance across numerous delivery orders spanning oncology treatments, specialty pharmaceuticals, biologics, vaccines, and routine medications supporting Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FDJL8?
SPE2DR26FDJL8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FDJL8 worth?
The government has obligated $11,771 on SPE2DR26FDJL8.
Is contract SPE2DR26FDJL8 an order under another contract?
Yes. SPE2DR26FDJL8 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJL8 competed?
The extent of competition for SPE2DR26FDJL8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award